RIBOLIFE-B (06938.HK): Positive Phase IIa Results for Core Asset Vortosiran in CAD; Maximum FXI Activity Reduction Reaches 92%

NewTimeSpace · 2026/07/22 16:45 · By Xuran Lin

NewTimeSpace News: Suzhou Ribo Life Science Co., Ltd. (06938.HK) announced positive top-line results from the Phase IIa clinical study of its core asset vortosiran (RBD4059) in patients with chronic coronary artery disease (CAD). Among patients receiving standard aspirin therapy, the mean maximum reduction in FXI activity hit 92% in the high-dose cohort. No treatment-related serious adverse events or major bleeding episodes were observed, supporting a dosing interval of once every 3 to 6 months. This represents the world’s first clinical proof-of-concept for siRNA-mediated FXI inhibition in CAD patients.

NewTimeSpace News: On 22 July 2026, Suzhou Ribo Life Science Co., Ltd. (06938.HK) released a voluntary announcement, unveiling positive Phase IIa clinical data of vortosiran (RBD4059) for chronic coronary artery disease (CAD) at the CPIC Global New Drug Summit.

This randomised, double-blind, placebo-controlled trial enrolled chronic CAD patients with prior myocardial infarction on aspirin therapy. Results demonstrated that among subjects completing the high-dose regimen with a maintenance dose of 400 mg, the mean maximum reduction in FXI activity reached 92% and sustained for months post-administration, supporting a dosing interval of once every 3 to 6 months. The magnitude of FXI suppression exceeds the projected efficacy of small-molecule candidates currently in Phase III development. Importantly, no treatment-related serious adverse events, major bleeding events or clinically relevant non-major bleeding events occurred throughout the study.

Vortosiran is a proprietary GalNAc-conjugated siRNA candidate built upon the Company’s RiboGalSTAR™ liver-targeting platform. It blocks the intrinsic coagulation pathway via specific inhibition of FXI synthesis to deliver potent antithrombotic activity. The above findings deliver the world’s first clinical proof-of-concept for siRNA-directed FXI inhibition in CAD patients and validate vortosiran’s development potential as a differentiated long-acting antithrombotic therapy.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

RIBOLIFE-B 06938.HK Clinical Data